Mechanism of action
Carvedilol is a non-selective beta-adrenergic receptor antagonist that blocks β1, β2, and α1-adrenergic receptors. The β1 blockade occurs primarily in the heart, reducing heart rate, myocardial contractility, and cardiac output. The β2 blockade affects bronchial and vascular smooth muscle. The α1-adrenergic blockade produces vasodilation, reducing peripheral vascular resistance and afterload.
The combined beta and alpha blockade results in decreased blood pressure through multiple mechanisms: reduced cardiac output (β1), decreased renin release from the kidneys (β1), and vasodilation (α1). In heart failure, carvedilol reduces sympathetic nervous system activation, which is chronically elevated and contributes to disease progression.
Carvedilol also possesses antioxidant properties that may protect against oxidative stress-mediated myocardial injury, though the clinical significance of this effect remains debated. Unlike pure beta-blockers, the vasodilatory α1 blockade may offset some of the negative hemodynamic effects of beta-blockade, potentially making it better tolerated in heart failure patients.
The non-selective nature means carvedilol does not exhibit the cardioselectivity seen with β1-selective agents like metoprolol or atenolol.
- Carvedilol is a non-selective β-blocker with α1-blocking activity, providing vasodilation and afterload reduction.
- One of three beta-blockers proven to reduce mortality in heart failure with reduced ejection fraction (HFrEF).
- Must be initiated at low doses and titrated slowly in heart failure patients to avoid decompensation.
- Contraindicated in decompensated heart failure, severe bradycardia, and second/third-degree AV block without pacemaker.
- Non-selective β2 blockade increases bronchospasm risk compared to cardioselective agents like metoprolol.
- Alpha-1 blockade causes orthostatic hypotension; patients should be counseled to rise slowly.
- Metabolized by CYP2D6 and CYP2C9; drug interactions with enzyme inhibitors increase carvedilol levels.
- Can mask hypoglycemia symptoms in diabetics and may worsen glycemic control and lipid profiles.
Indications
Heart failure with reduced ejection fraction (HFrEF): Carvedilol is a cornerstone therapy for chronic heart failure. Multiple landmark trials (COPERNICUS, CAPRICORN) demonstrated significant mortality reduction in HFrEF patients. It is typically initiated at low doses and titrated slowly in stable, euvolemic patients already receiving ACE inhibitors or ARBs and diuretics.
Hypertension: Approved for blood pressure control, though it is not typically a first-line agent for uncomplicated hypertension. The combined alpha and beta blockade provides effective BP reduction, particularly in patients with concurrent conditions like heart failure.
Left ventricular dysfunction following myocardial infarction: Carvedilol improves survival in clinically stable patients with left ventricular dysfunction after acute MI. It should be initiated after the patient is hemodynamically stable.
Off-label uses include prevention of variceal bleeding in portal hypertension, though non-selective beta-blockers without alpha activity (propranolol, nadolol) are more commonly used for this indication.
Pharmacokinetics
Absorption: Carvedilol is rapidly absorbed after oral administration but undergoes significant first-pass metabolism, resulting in absolute bioavailability of approximately 25-35%. Taking carvedilol with food slows the rate of absorption, which may reduce the risk of orthostatic hypotension, but does not change the overall extent of bioavailability.
Distribution: Carvedilol is highly lipophilic and more than 98% protein-bound in plasma, primarily to albumin. The volume of distribution is approximately 115 L.
Metabolism: Extensive hepatic metabolism occurs primarily via CYP2D6 and CYP2C9 pathways, with additional metabolism by CYP3A4, CYP2C19, and CYP1A2. Carvedilol undergoes oxidation and glucuronidation. Several metabolites have beta-blocking activity, though they are less potent than the parent compound. Genetic polymorphisms in CYP2D6 can affect drug levels, with poor metabolizers achieving higher plasma concentrations.
Elimination: Metabolites are eliminated primarily via bile into feces, with less than 2% excreted unchanged in urine. The elimination half-life is approximately 7-10 hours, but the duration of action may be longer due to active metabolites. Dosage adjustment is required in hepatic impairment but not typically in renal impairment.
Adverse effects
Cardiovascular: Bradycardia, hypotension, and orthostatic hypotension are common, particularly during initiation and dose titration. The alpha-blockade contributes to orthostatic symptoms. Heart failure decompensation can occur, especially with rapid titration. Peripheral edema may develop due to vasodilation.
Respiratory: Bronchospasm can occur due to β2 blockade, making carvedilol relatively contraindicated in patients with reactive airway disease or severe COPD. However, the risk is lower than with non-selective agents lacking alpha activity.
Metabolic: Carvedilol can mask hypoglycemia symptoms in diabetic patients and may worsen glycemic control. It can worsen lipid profiles, increasing triglycerides and decreasing HDL cholesterol. Weight gain is reported in some patients.
Neurological: Dizziness, fatigue, and headache are common. Depression and sleep disturbances including insomnia and nightmares can occur, though less commonly than with more lipophilic beta-blockers like propranolol.
Other effects: Sexual dysfunction, including erectile dysfunction, may occur. Carvedilol can worsen symptoms of peripheral vascular disease due to reduced cardiac output. Hepatotoxicity is rare but has been reported.
Withdrawal syndrome: Abrupt discontinuation can cause rebound tachycardia, hypertension, and precipitation of acute coronary syndromes. Carvedilol should be tapered gradually over 1-2 weeks when discontinuation is necessary.
Contraindications and warnings
Absolute contraindications include decompensated heart failure requiring inotropic support, severe bradycardia (heart rate <50 bpm), second- or third-degree AV block without a pacemaker, sick sinus syndrome without a pacemaker, cardiogenic shock, and severe hepatic impairment. Patients with known hypersensitivity to carvedilol should not receive the drug.
Relative contraindications and warnings include bronchospastic disease (asthma, severe COPD), as β2 blockade can precipitate bronchospasm. Peripheral vascular disease may worsen due to unopposed alpha-receptor stimulation in vascular beds. Patients with diabetes should be monitored closely as carvedilol can mask hypoglycemia symptoms and alter glucose metabolism.
Hepatic impairment: Carvedilol is contraindicated in severe hepatic dysfunction. Dose reduction is necessary in mild to moderate impairment due to reduced first-pass metabolism and increased bioavailability.
Pregnancy: Carvedilol is pregnancy category C (now replaced by PTHE system). Beta-blockers can cause fetal bradycardia, hypoglycemia, and intrauterine growth restriction. Use only if benefits outweigh risks. Carvedilol is excreted in breast milk; decision to continue breastfeeding should consider risk to infant.
Thyroid disease: Beta-blockers can mask clinical signs of hyperthyroidism (tachycardia, tremor). Abrupt withdrawal in hyperthyroid patients may precipitate thyroid storm.
Surgical patients: Continuation versus discontinuation perioperatively should be individualized. Beta-blocker withdrawal can increase perioperative cardiac events, but continuation may increase stroke and mortality risk in certain populations.
Drug interactions
CYP enzyme interactions: CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) and CYP2C9 inhibitors (fluconazole, amiodarone) can increase carvedilol levels, potentially increasing adverse effects. Rifampin, a CYP inducer, decreases carvedilol levels and may reduce efficacy.
Calcium channel blockers: Concurrent use of verapamil or diltiazem with carvedilol increases risk of bradycardia, AV block, and heart failure due to additive negative inotropic and chronotropic effects. Monitoring is essential if combination is necessary.
Digoxin: Carvedilol increases digoxin levels by approximately 15% through unknown mechanisms. Digoxin levels should be monitored when initiating carvedilol.
Antidiabetic agents: Beta-blockers can potentiate hypoglycemic effects of insulin and oral hypoglycemic agents while masking warning signs of hypoglycemia (tachycardia, tremor). More frequent glucose monitoring is warranted.
Clonidine: Concurrent use with beta-blockers can increase risk of rebound hypertension if clonidine is discontinued. Beta-blockers should be withdrawn several days before tapering clonidine.
Anesthetics: Carvedilol may enhance myocardial depressant effects of general anesthetics, increasing risk of hypotension and bradycardia.
Cyclosporine: Carvedilol may increase cyclosporine concentrations, requiring dose adjustment and close monitoring of cyclosporine levels.
Reserpine or MAO inhibitors: May have additive effects, causing marked bradycardia and hypotension.
Clinical pearls
- Start low, go slow: In heart failure, carvedilol must be initiated at low doses and titrated slowly every 2 weeks as tolerated to target doses. Rapid titration increases risk of decompensation.
- Mortality benefit: Carvedilol is one of only three beta-blockers (along with metoprolol succinate and bisoprolol) with proven mortality reduction in heart failure with reduced ejection fraction.
- Non-selective means more side effects: Unlike cardioselective beta-blockers, carvedilol blocks β2 receptors, increasing bronchospasm risk and peripheral vascular effects.
- Alpha-blockade differentiates it: The α1 blockade provides additional afterload reduction but also increases orthostatic hypotension risk. Counsel patients to rise slowly from sitting or lying positions.
- Take with food: Administration with food slows the rate of absorption, which may reduce orthostatic hypotension risk.
- Immediate-release versus extended-release: Both formulations are available. Extended-release allows once-daily dosing and may improve compliance.
- Not all beta-blockers are equal in HF: Atenolol and metoprolol tartrate have NOT shown mortality benefit in heart failure. Only sustained-release formulations and specific agents (carvedilol, metoprolol succinate, bisoprolol) should be used.
- Paradox in heart failure: While beta-blockers acutely reduce contractility, chronic use improves ejection fraction and survival by reducing toxic effects of chronic sympathetic activation.
- Perioperative considerations: Current guidelines generally support continuing beta-blockers in patients already taking them chronically, but initiating them perioperatively in beta-blocker-naive patients may increase stroke risk.
Practice questions
1. A 62-year-old man with a history of myocardial infarction 6 months ago presents for follow-up. Echocardiography shows a left ventricular ejection fraction of 30%. He is currently on lisinopril and furosemide and reports stable dyspnea with moderate exertion. Blood pressure is 118/76 mmHg, heart rate is 82/min. Which medication should be added to improve his long-term survival?
2. A 58-year-old woman with heart failure is started on low-dose carvedilol. Two weeks later, she reports feeling dizzy when standing up from a seated position, especially in the morning. Her blood pressure is 108/68 mmHg sitting and 88/60 mmHg standing. Heart rate decreases from 68 to 64/min with standing. Which property of carvedilol best explains her symptoms?
3. A 55-year-old man with hypertension and heart failure on carvedilol at target dose is admitted with acute decompensated heart failure. Physical examination reveals bilateral rales, elevated JVP, and bilateral lower extremity edema. Blood pressure is 92/58 mmHg, heart rate 56/min. After diuresis and clinical stabilization, what is the most appropriate management of his carvedilol?
Frequently asked questions
How does carvedilol work?
Carvedilol blocks β1, β2, and α1-adrenergic receptors. The beta-blockade reduces heart rate, contractility, and cardiac output, while alpha-1 blockade causes vasodilation and reduces peripheral vascular resistance. This combination decreases blood pressure and reduces the workload on the heart. In heart failure, carvedilol counteracts the toxic effects of chronic sympathetic nervous system activation, improving ventricular remodeling and survival.
What are the side effects of carvedilol?
Common side effects include dizziness, fatigue, hypotension, bradycardia, and orthostatic hypotension due to combined beta and alpha blockade. Bronchospasm can occur in patients with reactive airway disease due to non-selective beta-2 blockade. Other effects include weight gain, worsening glycemic control in diabetics, masking of hypoglycemia symptoms, sexual dysfunction, and peripheral edema. Rarely, hepatotoxicity has been reported. Heart failure patients may experience temporary worsening during initiation.
What is the difference between carvedilol and metoprolol?
Carvedilol is a non-selective beta-blocker that blocks β1, β2, and α1 receptors, providing vasodilation, while metoprolol is β1-selective (cardioselective) and does not block alpha receptors. Both reduce mortality in heart failure when using sustained-release formulations. Carvedilol has higher risk of bronchospasm and orthostatic hypotension due to its non-selective nature and alpha blockade. Metoprolol is generally better tolerated in patients with lung disease.
Can carvedilol be stopped suddenly?
No, carvedilol should not be stopped abruptly. Sudden discontinuation can cause rebound tachycardia, severe hypertension, and may precipitate acute coronary syndromes or heart failure decompensation due to upregulation of adrenergic receptors during chronic beta-blockade. If discontinuation is necessary, carvedilol should be tapered gradually over 1-2 weeks with close monitoring of heart rate, blood pressure, and symptoms, especially in patients with coronary artery disease or heart failure.
Is carvedilol safe in diabetes?
Carvedilol can be used in diabetic patients but requires caution. It may mask symptoms of hypoglycemia such as tachycardia and tremor, making it harder for patients to recognize low blood sugar. Carvedilol can also worsen glycemic control and adversely affect lipid profiles. Despite these concerns, the cardiovascular benefits, particularly in heart failure, generally outweigh the risks. Diabetic patients on carvedilol need more frequent blood glucose monitoring and education about atypical hypoglycemia symptoms.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C07AG02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.